If you run a health tech or medical device company and you have only ever looked at NIH, there is a good chance you are missing a funder that hands out more than $1 billion a year for disease research. It is called CDMRP, and the way it decides what to fund is different enough that most founders get the strategy wrong before they write a single word.
The key word is "programmatic." CDMRP runs a panel that sets the investment vision for each disease program before proposals are reviewed. Learning to read CDMRP programmatic panel priorities is the single most useful thing you can do before writing anything, because that vision is the whole game. Cada has written more than 100 grant proposals across 30-plus agencies, and the process below is the one we use to decide whether CDMRP is worth a founder's time.
What is a CDMRP programmatic panel? A CDMRP programmatic panel, formally an Integration Panel, is a standing committee of scientists, clinicians, and patient advocates that sets a disease program's yearly investment strategy and then decides which peer-reviewed applications actually get funded. It shapes the vision before proposals arrive and picks winners after peer review.
That two-step role is why CDMRP alignment works differently from NIH. This guide walks through how the programmatic panel process works, how to read a CDMRP Program Announcement, which award mechanisms fit a startup, whether for-profit companies can even apply, and how four specific disease programs map their panel priorities to real funding mechanisms.
What is a CDMRP programmatic panel?
CDMRP stands for the Congressionally Directed Medical Research Programs. It is managed by the U.S. Army Medical Research and Development Command, not by NIH or the general defense research budget.
Each disease program (breast cancer, prostate cancer, ALS, and roughly 30 others) has an Integration Panel. Practitioners often call it the programmatic panel. It does two jobs most other funders split up or skip.
First, it sets the vision. Before a funding cycle opens, the panel decides what the program is trying to achieve that year and which gaps matter most. That decision becomes the Program Announcement.
Second, it makes the final funding call. After scientific peer review scores each application on merit, the same panel reviews the strongest applications and chooses which ones to fund based on the program's portfolio and priorities.
Here is the part that surprises founders: patient advocates sit on that panel with a real vote. A breast cancer survivor helps decide which breast cancer research gets funded. That consumer advocate voice is a defining feature of CDMRP, and it shapes what "impact" means in a winning proposal.
How CDMRP decides what to fund
How does CDMRP decide what to fund? CDMRP uses a two-tier review. Tier one is scientific peer review, which scores each application on merit much like an NIH study section. Tier two is programmatic review, where the Integration Panel selects fundable applications from the meritorious pile based on the year's vision and portfolio balance. A strong score alone does not guarantee funding.
That second tier is the difference that changes your strategy.
At NIH, your score largely determines your fate. A study section of 15 to 20 scientists scores your application, the percentile drives the funding decision, and the institute funds down the list until the money runs out. Portfolio fit matters, but the score dominates.
At CDMRP, a fundable peer-review score gets you into the room. It does not get you the money. The programmatic panel then asks a different question: does this application advance what we said we care about this year, and does it fill a gap the rest of our portfolio is missing?
Two applications with nearly identical scientific scores can get opposite decisions. The one that maps cleanly onto the panel's stated vision wins. The one that is excellent but off-theme does not.
| Dimension | NIH study section | CDMRP two-tier review |
|---|---|---|
| Who scores merit | Study section of 15-20 scientists | Scientific peer review panel |
| Who decides funding | Institute, largely by percentile | Programmatic Integration Panel |
| Patient advocates | Rare, mostly advisory | Voting members of the panel |
| Deciding factor | Score / percentile | Score plus portfolio and vision fit |
| Vision set in advance | Broad institute priorities | Program-specific annual investment strategy |
The practical takeaway: at CDMRP, being right about the science is necessary but not sufficient. Being aligned with the panel's published vision is what separates funded from unfunded.
Where the money comes from (and why "Congressionally Directed" matters)
The name is not decoration. Each year Congress directs specific dollars to specific disease research inside the Defense Health Program appropriation. That is why it is "congressionally directed."
This has two consequences you need to plan around.
First, the budget changes every year. A program funded at a certain level this year could be higher, lower, or flat next year depending on the appropriation. Recent years have put total CDMRP funding above $1 billion annually across all programs, with figures reported around $1.5 billion in some years, per publicly reported congressional appropriations compiled in Cada's agency research. To be blunt, the exact number for any single program is a moving target, so treat published amounts as recent history, not a guarantee.
Second, because the money flows through the Defense Health Program, every program expects a connection to the military mission or to service members, veterans, and their families. This is the "military relevance" requirement, and it trips up founders who treat CDMRP like a second NIH.
Military relevance does not mean your technology has to be a weapon or a battlefield device. It means you have to explain why this disease matters to the military community. Breast cancer affects service members and military families. PTSD and traumatic brain injury are directly tied to deployment. Some cancers show higher rates in veterans exposed to specific hazards. If you cannot draw that line honestly, CDMRP is probably not your program.
How to read a CDMRP Program Announcement strategically
The Program Announcement, usually shortened to PA, is where the programmatic panel's vision becomes concrete. Most founders skim it for the deadline and the award ceiling. That is a mistake. The PA tells you exactly what the panel wants to buy this year.
Here is a five-step way to read one.
-
Read the vision and mission statement first. Every program states what it is trying to achieve. Breast cancer aims at eradication. ALS aims at treatments and a path to cure. Read this before anything else, because every mechanism below it exists to serve that vision.
-
Find this year's focus areas or overarching challenges. These are the specific gaps the panel wants filled this cycle. They change year to year. A focus area is a strong hint about what the panel will reward in tier-two review.
-
List the award mechanisms offered this year. Not every mechanism runs every year. The mechanisms on offer tell you what stage of work the panel is prioritizing, from early ideas to clinical trials.
-
Check partnership and eligibility requirements. Some mechanisms require a clinical collaborator, an early-career partner, or a consumer advocate on the team. Some encourage industry partnerships. Missing a required partnership is an automatic administrative rejection.
-
Map your military relevance argument. Decide, before you commit, how you will connect your disease and technology to the military mission. If that argument is weak, stop here.
If you do these five steps and your work lines up with a stated focus area under a mechanism you qualify for, you have found real alignment. If you are stretching to fit, the panel will see the stretch.
CDMRP award mechanisms: which ones fit a startup
CDMRP does not use one application type. Each program offers a menu of award mechanisms, and they are built for different stages of evidence. Picking the wrong mechanism is one of the most common avoidable errors.
| Mechanism family | What it funds | Preliminary data? | Startup fit |
|---|---|---|---|
| Concept / Idea | Untested, novel, high-risk ideas | Usually little or none | High for early science |
| Investigator-Initiated | Defined research questions with a hypothesis | Often expected | Medium, PI-driven |
| Technology / Therapeutic Development | Moving a product or therapy toward the clinic | Yes, product-focused | High for companies |
| Clinical Trial | Testing an intervention in people | Strong preclinical or prior data | High if trial-ready |
| Career Development | Building an early-career investigator | Varies | Low for companies |
| Breakthrough (program-specific) | Tiered awards from early to large-scale | Varies by tier | Medium to high |
For a company rather than an academic lab, two families usually fit best.
Technology or Therapeutic Development awards are built for exactly what startups do: taking something that works in principle and pushing it toward a real product or clinical use. These reward a credible development plan, not just a novel hypothesis.
Idea or Concept awards fit when your science is genuinely new and you do not yet have preliminary data. They are meant to fund high-risk, high-reward directions that traditional funders would call premature.
The dollar figures separate these two clearly. Concept and Idea awards are the small end, often in the range of $100,000 to a few hundred thousand dollars over 1 to 2 years. Technology and Therapeutic Development awards are the large end, commonly running from roughly $1 million to $4 million or more over 2 to 4 years. Clinical Trial awards can run higher still, into the multiple millions. These are approximate ranges, not fixed numbers: every ceiling and project period is set per mechanism in each year's Program Announcement, so confirm the exact figure there before you plan a budget.
The lesson from the mechanism menu: match the mechanism to the evidence you actually have. A company with a working prototype and a clinical partner should not apply through an early Idea mechanism, and a company with a bright hypothesis and no data should not reach for a Clinical Trial award.
Can for-profit startups apply to CDMRP?
Can for-profit companies apply to CDMRP? Yes. Most CDMRP award mechanisms are open to for-profit organizations, including startups, and there is no small-business size cap like the one SBIR uses. Academia, industry, and government can all apply, a principal investigator can often be based at a company, and clinical partnerships are frequently encouraged.
This is a real advantage over programs that gate on company size or nonprofit status.
SBIR and STTR limit you to small businesses under a specific size and ownership rules. CDMRP generally does not. A company of any size can apply to most mechanisms, which means CDMRP stays open to you even after you outgrow SBIR eligibility.
One honest caveat: eligibility is set per mechanism inside each Program Announcement. A specific mechanism in a specific year might restrict applicants or require an academic partner. So the rule is "most mechanisms are open to for-profits," and the verification is "confirm it in this year's PA for the exact mechanism you want."
Four disease programs and how their panel priorities map to mechanisms
The abstract process gets concrete when you look at how specific programs turn their panel's vision into mechanisms. Here are four, with illustrative scenarios. The companies below are fictional and used only to show the pattern.
Breast Cancer Research Program
The vision is explicit: end breast cancer. The programmatic panel has historically pushed on prevention, on stopping metastasis, and on the biology of lethal disease rather than incremental screening tweaks.
The program is known for Breakthrough Awards, which are tiered so that early-stage ideas and large-scale efforts each have a lane. Recent-year appropriations for this program have been in the rough range of $130 million to $150 million, though Congress resets that annually.
Illustrative scenario: a fictional company with a blood test that flags breast cancer recurrence earlier than current follow-up would read the panel's metastasis focus, then choose a Breakthrough tier that matches its evidence stage rather than defaulting to the largest award.
Prostate Cancer Research Program
The panel has emphasized lethal prostate cancer and health disparities, including why some populations face worse outcomes. Recent appropriations have been in the rough range of $110 million a year.
A fictional startup with an imaging tool that distinguishes aggressive from indolent prostate tumors would map directly onto the "lethal disease" priority and frame its military relevance around veteran incidence.
Amyotrophic Lateral Sclerosis (ALS) Research Program
The ALS program's vision is treatments and a path toward a cure, with a strong pull toward moving therapies forward. Therapeutic Development and Clinical Trial mechanisms fit that pull.
A fictional biotech with a neuroprotective compound that cleared early animal studies would target a Therapeutic Development mechanism, because the panel is buying progress toward the clinic, not another early hypothesis.
Psychological Health and PTSD research (military mental health)
Mental health tied to deployment is close to the core of the Defense Health mission, so military relevance is straightforward here. The panels in this space have prioritized deployment-related conditions, including PTSD and traumatic brain injury, and they welcome both clinical studies and technology-enabled care.
A fictional company with a wearable that tracks PTSD symptom patterns between therapy sessions would connect its technology to service-member care and choose a mechanism that supports either a clinical study or a technology development path.
| Program | Panel vision hook | Best-fit mechanism | For-profit friendly? |
|---|---|---|---|
| Breast Cancer | Eradication, metastasis, prevention | Breakthrough (tiered) | Yes |
| Prostate Cancer | Lethal disease, disparities | Idea Development, Clinical | Yes |
| ALS | Therapies, path to cure | Therapeutic Development, Clinical Trial | Yes |
| Psychological Health / PTSD | Deployment-related conditions | Clinical, Technology Development | Yes |
A four-step method to decide if CDMRP fits your company
You do not need to become a CDMRP expert to make a good decision. You need four steps.
-
Match your disease area to a program. If your technology targets breast cancer, prostate cancer, ALS, PTSD, and roughly 30 other conditions, there may be a dedicated program. If not, check the Peer Reviewed Medical Research Program, which covers a rotating list of congressionally designated topic areas, and the Peer Reviewed Cancer Research Program for cancers without their own program.
-
Read this year's Program Announcement vision and focus areas. Confirm the panel is prioritizing something your work actually addresses. If you are stretching to fit, that is your answer.
-
Pick the mechanism that matches your evidence. No data yet means an Idea or Concept mechanism. A working prototype and a clinical partner means a Technology or Therapeutic Development mechanism. Trial-ready means a Clinical Trial mechanism.
-
Frame your military relevance honestly. Write one clear sentence connecting your disease and technology to the military community. If you cannot, CDMRP is likely not the right program, and that is useful to know early.
If you have no dedicated program, weak military relevance, and no clear mechanism fit, walk away and put your time into NIH or SBIR. Knowing when not to apply is worth as much as knowing when to.
Frequently asked questions
Is CDMRP part of the DoD or NIH? CDMRP is part of the Department of Defense, managed by the U.S. Army Medical Research and Development Command. It is funded through the Defense Health Program appropriation, not through NIH, even though it funds biomedical research that looks similar to NIH's.
How much does CDMRP award each year? Total CDMRP funding has exceeded $1 billion a year in recent years across all programs, with some years reported near $1.5 billion. Congress sets the amount for each disease program annually, so individual program budgets change year to year.
Do I need preliminary data to apply to CDMRP? It depends on the mechanism. Idea and Concept awards are designed for high-risk work with little or no preliminary data. Investigator-Initiated, Technology Development, and Clinical Trial awards generally expect data appropriate to that stage. Match the mechanism to the evidence you have.
What is the difference between CDMRP peer review and programmatic review? Peer review scores your application on scientific merit, similar to an NIH study section. Programmatic review, done by the Integration Panel, then selects which meritorious applications to fund based on the program's vision and portfolio. You need both a fundable score and portfolio fit.
Can a company be the applicant, or do I need a university? Most CDMRP mechanisms are open to for-profit organizations, and a principal investigator can often be based at a company. Some mechanisms encourage or require partnerships, such as a clinical collaborator. Confirm the specific rules in this year's Program Announcement for your chosen mechanism.
When are CDMRP Program Announcements released? Program Announcements are released on a program-by-program schedule, typically after Congress finalizes the appropriation and the programmatic panel sets that year's vision. Because the timing shifts with the federal budget cycle, check the official CDMRP program pages for current dates rather than assuming a fixed month.
Where CDMRP fits in a multi-agency grant strategy
Most founders treat federal grants as a single decision: NIH or nothing. That is how a $1 billion-plus funder for your exact disease area stays invisible.
The smarter frame is a portfolio. NIH and CDMRP have different review dynamics, different vision-setting, and often different competition for the same science. A proposal that struggles to place at NIH can be a strong fit for a CDMRP program whose panel is prioritizing exactly your gap this year.
That is the real reason to learn CDMRP programmatic panel priorities. It lets you read CDMRP the way the panel reads you, and it opens a second serious funding path for the work you are already doing.
If you have been applying only to NIH, the first question is not "how do I write a CDMRP application." It is "is there a CDMRP program that fits my disease, my evidence stage, and a real military relevance argument." That is a fit question, and it takes about 15 minutes to answer honestly.
If you want a straight answer on whether CDMRP fits your company, that is exactly the kind of thing a free CDMRP fit assessment is for: no pitch, just whether there is a program worth your time. And if there is, the next move is a multi-agency roadmap that sequences CDMRP alongside NIH so you are not betting your entire non-dilutive funding plan on one agency.